Indalo Therapeutics

Indalo Therapeutics is discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as NASH and IPF. Indalo’s novel chemistry is unique as it provides target specificity in small molecules with favorable drug metabolism and pharmacokinetic properties. The company’s lead drug candidate, IDL-2965, is scheduled to enter the clinic in early 2019.

Headquarters Cambridge, MA
Website indalotherapeutics.com
Pipeline Phase 1
Twitter @indalotx‚Äč